GSK to invest £400m in UK R&D and cut costs by £1.9bn

GSK CEO Luke Miels on Tuesday, July 28, 2026, announced a major strategic shift for the British pharmaceutical giant, centered on a significant new investment in UK research and a sweeping cost-savings program designed to accelerate drug development. The dual initiatives aim to revitalize the company's pipeline ahead of critical patent expiries and strengthen its competitive position.

The company will invest 400 million pounds over three years in the UK, with a cornerstone being a new 300,000-square-foot research and development center in Cambridge. The facility, set to house more than 1,000 scientists, will focus on core therapeutic areas including oncology and respiratory diseases. As part of this consolidation, GSK will vacate its existing R&D site in Stevenage by 2029 and upgrade its facility in Ware.

Concurrently, GSK launched a three-year efficiency program targeting 1.9 billion pounds in annual savings by 2029. CEO Luke Miels stated the savings would be largely reinvested to advance the company's late-stage portfolio. While the company did not specify the number of job cuts, the savings drive is expected to involve layoffs in back-office functions and a reallocation of...